Date:2/4/2010

g, general and administrative 138,968 27.2 138,495 27.2 Amortization 3,110 0.6 2,753 0.5 Interest expense 6,142 1.2 6,667 1.3 Other charges (income), net 3,205 0.7 6,361 1.2 ----- --- ----- --- Earnings before taxes 94,832 18.5 85,191 16.7 Provision for taxes 25,394 4.9 22,267 4.4 ------ --- ------ --- Net earnings $69,438 13.6 $62,924 12.3 ======= ==== ======= ==== Basic earnings per common share: Net earnings $2.05 $1.88 Weighted average number of common shares 33,815,082 33,553,946 Diluted earnings per common share: Net earnings $2.01 $1.84 Weighted average number of common and common equivalent shares 34,560,581 34,153,116 Note: (a) Local currency sales decreased 5% as compared to the same period in 2008. RECONCILIATION OF EARNINGS BEFORE TAXES TO ADJUSTED OPERATING INCOME Three months ended % Three months ended % December 31, 2009 of sales December 31, 2008 of sales Earnings before taxes $94,832 $85,191 Amortization 3,110 2,753 Interest expense 6,142 6,667 Other charges (income), net 3,205 (b) 6,361 (b) ----- -
'/>"/>

SOURCE Mettler-Toledo International Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine technology :

1. Mettler-Toledo International Inc. Reports Third Quarter 2009 Results
2. Mettler-Toledo International Inc. Announces Webcast of Presentation at Baird Industrial Conference
3. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
4. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
8. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
9. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
11. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers